Table 1 Summary of included studies
First author | Year | Study design | Follow-up period for outcomes | Reported outcomes | Fluid type | Number of total patients |
|---|---|---|---|---|---|---|
Young | 2015 | Multi-center double-blind, cluster randomized, double-crossover trial | 90 days after randomizations for all variables | Hospital and ICU mortality, AKI and RRT | Plasma-Lyte | 1152 |
Saline | 1110 | |||||
Verma | 2016 | Multi-center double-bind randomized controlled trial | AKI during the first 4 days while other outcomes till discharge | Hospital and ICU mortality, AKI and RRT | Plasma-Lyte | 33 |
Saline | 34 | |||||
Semler (SMART trial) | 2018 | Single center unblinded, cluster randomized, multiple crossover trial | Death at 60 days, AKI after enrollment, RRT at 28 days. | Hospital and ICU mortality, AKI and RRT | LR or Plasma-Lyte | 7942 |
Saline | 7860 | |||||
Semler (SALT trial) | 2016 | Single-center prospective, open-label, cluster-randomized, multiple crossover trial | Death at 60 days, AKI after enrollment, RRT at 28 days. | Hospital and ICU mortality, AKI and RRT | LR or Plasma-Lyte | 520 |
Saline | 454 | |||||
Young | 2014 | Single center randomized, double-blind, parallel-group clinical trial | In-hospital mortality at 30 days | Hospital mortality | Plasma-Lyte | 22 |
Saline | 24 | |||||
Ratanarat | 2017 | Single-center randomized controlled trial | AKI during the first 7 days | AKI and RRT | Balanced | 88 |
Saline | 93 |